<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336646</url>
  </required_header>
  <id_info>
    <org_study_id>2012-02-070B</org_study_id>
    <nct_id>NCT02336646</nct_id>
  </id_info>
  <brief_title>Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease</brief_title>
  <official_title>Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Bio Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Bio Therapeutics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions&#xD;
      using medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study&#xD;
      in treating 18 recipients with ischemic limb diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic limb disease remains one of the major causes of morbidity and mortality in the&#xD;
      industrialized world despite the development of several new therapeutic modalities. Based on&#xD;
      experimental data demonstrating that infusion or injection of stem/progenitor cells enhances&#xD;
      blood flow in models of cardiovascular diseases, clinical trials were initiated in 2001 to&#xD;
      treat patients with critical limb ischemia or cardiac ischemia with circulating blood or bone&#xD;
      marrow-derived cells. Despite all promises, pending uncertainties and practical limitations&#xD;
      attenuate the therapeutic use of stem/progenitor cells for ischemic limb disease. The main&#xD;
      theme and method in the current program project, based on expertise, track record, and&#xD;
      preliminary results of PI's laboratory, is to focus on clinical studies of using allogenic&#xD;
      mesenchymal stem cells (MSCs), expanded under hypoxic conditions (1% O2), in treating&#xD;
      ischemic limbs. This project is an integrated and coordinated effort aimed to overcome the&#xD;
      regulation of cell product, and the barriers of preclinical and clinical studies. For the&#xD;
      purposes, we have specially set up the core laboratory for stem/progenitor cells production&#xD;
      and quality control in Cell Therapy Clean Room on the 9th floor of Medical Science Technology&#xD;
      Building in Taipei Veterans General Hospital. We have also completed the preclinical studies&#xD;
      in using allogenic hypoxic mouse MSCs in treating limb ischemia. In the current project, bone&#xD;
      marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions using&#xD;
      medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study in&#xD;
      treating 18 recipients with ischemic limb diseases in three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">December 20, 2018</completion_date>
  <primary_completion_date type="Actual">April 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of adverse events reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy-The Wong Baker FACES® pain rating scale</measure>
    <time_frame>6 months</time_frame>
    <description>The Wong Baker FACES® pain rating scale, for evaluation of ischemic pain in the diseased lower limb of subjects receiving cell injection compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy-Transcutaneous oxygen pressure(TcPO2)</measure>
    <time_frame>6 months</time_frame>
    <description>The Transcutaneous oxygen pressure (TcPO2) on foot of subjects receiving cell injection compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy-walking distance (TWD)</measure>
    <time_frame>6 months</time_frame>
    <description>Total walking distance (TWD) on a standardized treadmill test compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy-Ankle Brachial Pressure Index (ABPI)</measure>
    <time_frame>6 months</time_frame>
    <description>The Ankle Brachial Pressure Index (ABPI) in the lower limb of subjects receiving cell injection compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Low Dose Allogenic MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose allogenic mesenchymal stem cells with IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Allogenic MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose allogenic mesenchymal stem cells with IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline with Intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogenic MSC</intervention_name>
    <description>Hypoxia-cultured human bone marrow derived mesenchymal stem cells</description>
    <arm_group_label>High Dose Allogenic MSC</arm_group_label>
    <arm_group_label>Low Dose Allogenic MSC</arm_group_label>
    <other_name>Biochymal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fontaine stage &gt; II, total walking distance &lt; 100 m, stair &lt; 1 floor, or ulcer /&#xD;
             necrosis&#xD;
&#xD;
          -  Established critical limb ischemia, clinically and hemodynamically confirmed as per&#xD;
             Rutherford- Ⅱ-4, Ⅲ-5, or Ⅲ-6; Patients having Infra-inguinal arterial occlusive&#xD;
             disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have&#xD;
             failed traditional revascularization treatment&#xD;
&#xD;
          -  Ankle Brachial Pressure Index (ABPI) ≤ 0.8，ankle pressure ≤ 70 mm Hg, or TcPO2 ≤ 70&#xD;
             mmHg in the foot&#xD;
&#xD;
          -  No response to medication (aspirin and cilostazol)&#xD;
&#xD;
          -  Normal liver and renal function&#xD;
&#xD;
          -  On regular medication for hypertension if any&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The above mentioned patients combined with infection or systemic septicemia. (ps,&#xD;
             patients with poor control of diabetes, hypertension and hyperlipidemia will also be&#xD;
             excluded&#xD;
&#xD;
          -  Patient with Immunocompromised or immunosuppressed&#xD;
&#xD;
          -  Type I Diabetes&#xD;
&#xD;
          -  Patients having stroke or myocardial infarction within last 3 months&#xD;
&#xD;
          -  Hb% &lt; 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c &gt; 8%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Che Shih</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

